Literature DB >> 15044926

Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome.

N A Heerema1, J Harbott, S Galimberti, B M Camitta, P S Gaynon, G Janka-Schaub, W Kamps, G Basso, C-H Pui, M Schrappe, M-F Auclerc, A J Carroll, V Conter, C J Harrison, J Pullen, S C Raimondi, S Richards, H Riehm, H N Sather, J J Shuster, L B Silverman, M G Valsecchi, M Aricò.   

Abstract

Additional chromosomal aberrations occur frequently in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) of childhood. The treatment outcome of these patients is heterogeneous. This study assessed whether such clinical heterogeneity could be partially explained by the presence and characteristics of additional chromosomal abnormalities. Cytogenetic descriptions were available for 249 of 326 children with Ph+ ALL, diagnosed and treated by 10 different study groups/large single institutions from 1986 to 1996. Secondary aberrations were present in 61% of the cases. Chromosomes 9, 22, 7, 14, and 8 were most frequently abnormal. Most (93%) karyotypes were unbalanced. Three main cytogenetic subgroups were identified: no secondary aberrations, gain of a second Ph and/or >50 chromosomes, or loss of chromosome 7, 7p, and/or 9p, while other secondary aberrations were grouped as combinations of gain and loss or others. Of the three main cytogenetic subgroups, the loss group had the worst event-free survival (P=0.124) and disease-free survival (P=0.013). However, statistical significance was not maintained when adjusted for other prognostic factors and treatment. Karyotypic analysis is valuable in subsets of patients identified by molecular screening, to assess the role of additional chromosomal abnormalities and their correlation with clinical heterogeneity, with possible therapeutic implications.

Entities:  

Mesh:

Year:  2004        PMID: 15044926     DOI: 10.1038/sj.leu.2403324

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  17 in total

1.  Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.

Authors:  Maurizio Aricò; Martin Schrappe; Stephen P Hunger; William L Carroll; Valentino Conter; Stefania Galimberti; Atsushi Manabe; Vaskar Saha; André Baruchel; Kim Vettenranta; Keizo Horibe; Yves Benoit; Rob Pieters; Gabriele Escherich; Lewis B Silverman; Ching-Hon Pui; Maria Grazia Valsecchi
Journal:  J Clin Oncol       Date:  2010-09-27       Impact factor: 44.544

2.  Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Authors:  Ibrahim Aldoss; Tracey Stiller; Thai M Cao; Joycelynne M Palmer; Sandra H Thomas; Stephen J Forman; Vinod Pullarkat
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-01       Impact factor: 5.742

3.  Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.

Authors:  Nicholas J Short; Hagop M Kantarjian; Koji Sasaki; Farhad Ravandi; Heidi Ko; C Cameron Yin; Guillermo Garcia-Manero; Jorge E Cortes; Rebecca Garris; Susan M O'Brien; Keyur Patel; Maria Khouri; Deborah Thomas; Nitin Jain; Tapan M Kadia; Naval G Daver; Christopher B Benton; Ghayas C Issa; Marina Konopleva; Elias Jabbour
Journal:  Am J Hematol       Date:  2017-02-03       Impact factor: 10.047

4.  Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.

Authors:  William B Slayton; Kirk R Schultz; John A Kairalla; Meenakshi Devidas; Xinlei Mi; Michael A Pulsipher; Bill H Chang; Charles Mullighan; Ilaria Iacobucci; Lewis B Silverman; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Julie M Gastier-Foster; Brent L Wood; Sherri L Mizrahy; Thomas Merchant; Valerie I Brown; Lance Sieger; Marilyn J Siegel; Elizabeth A Raetz; Naomi J Winick; Mignon L Loh; William L Carroll; Stephen P Hunger
Journal:  J Clin Oncol       Date:  2018-05-29       Impact factor: 44.544

5.  Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors.

Authors:  Jesse Jaso; Deborah A Thomas; Krista Cunningham; Jeffrey L Jorgensen; Hagop M Kantarjian; L Jeffrey Medeiros; Sa A Wang
Journal:  Cancer       Date:  2011-03-01       Impact factor: 6.860

6.  Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.

Authors:  Richard T Williams; Willem den Besten; Charles J Sherr
Journal:  Genes Dev       Date:  2007-08-30       Impact factor: 11.361

7.  Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.

Authors:  Aurélie Caye; Kheïra Beldjord; Kelly Mass-Malo; Séverine Drunat; Jean Soulier; Virginie Gandemer; André Baruchel; Yves Bertrand; Hélène Cavé; Emmanuelle Clappier
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

8.  High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.

Authors:  Faith M Young; Andrew Campbell; Kris Lambert Emo; Johan Jansson; Pin-Yi Wang; Craig T Jordan; Craig A Mullen
Journal:  Biol Blood Marrow Transplant       Date:  2008-04-14       Impact factor: 5.742

Review 9.  Cytogenetics and molecular genetics of acute lymphoblastic leukemia.

Authors:  Krzysztof Mrózek; David P Harper; Peter D Aplan
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

10.  High modal number and triple trisomies are highly correlated favorable factors in childhood B-cell precursor high hyperdiploid acute lymphoblastic leukemia treated according to the NOPHO ALL 1992/2000 protocols.

Authors:  Kajsa Paulsson; Erik Forestier; Mette K Andersen; Kirsi Autio; Gisela Barbany; Georg Borgström; Lucia Cavelier; Irina Golovleva; Sverre Heim; Kristiina Heinonen; Randi Hovland; Johann H Johannsson; Eigil Kjeldsen; Ann Nordgren; Lars Palmqvist; Bertil Johansson
Journal:  Haematologica       Date:  2013-05-03       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.